Medimmune Oncology Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MEDIMMUNE ONCOLOGY, and what generic and branded alternatives to MEDIMMUNE ONCOLOGY drugs are available?
MEDIMMUNE ONCOLOGY has one approved drug.
Drugs and US Patents for Medimmune Oncology
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-002 | Jul 31, 1998 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Medimmune Oncology
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | 4,376,858 | ⤷ Subscribe |
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-002 | Jul 31, 1998 | 6,017,922 | ⤷ Subscribe |
Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | 4,694,007 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.